Home' Australian Pharmacist : Australian Pharmacist January 2013 Contents 52
Australian Pharmacist January 2013 I ©Pharmaceutical Society of Australia Ltd.
SUPPORTING PHARMACY PRACTICE
CPD that comes to you...
Quality CPD, anytime, anywhere
Automatic recording of your CPD credits
Choose from over 80 activities
PSA online CPD
PSA All you need for your CPD.
1. Which of the following would
be considered a remunerable
clinical intervention under the 5th
Community Pharmacy Agreement?
a) Providing a blood pressure check for a
client with diabetes who requests it.
b) Identifying a drug-drug interaction
and querying this with the prescriber.
c) Packing medication in a dosage
d) Recommending a S3 Pharmacist Only
Medicine to treat a minor ailment.
2. Recording clinical interventions is
a) Payment is in part linked to the
number of interventions made.
b) It permits evaluation and audit.
c) Communication with colleagues
regarding follow-up is facilitated.
d) All of the above.
3. Best practice in terms of delivering
clinical interventions includes all of
the following EXCEPT:
a) Documenting interventions clearly.
b) Collecting the information
necessary to formulate appropriate
c) Explaining to clients that the
prescriber has made a mistake.
d) Making better health outcomes for
consumers a priority.
4. Glenda is a 71-year-old woman
with breast cancer, depression,
dyslipidaemia and hypertension,
whose current medication
regimen is anastrozole 1 mg
daily, venlafaxine MR 225 mg
daily, simvastatin 80 mg daily and
verapamil MR 180 mg daily. Which
of the following DRPs would be
best classified as an ‘Undertreated’
intervention using the DOCUMENT
a) Concern about myopathy risk with
high-dose simvastatin and verapamil.
b) Concern about the risk of anastrozole-
related adverse effects on bone.
c) Concern about venlafaxine increasing
blood pressure at doses > 200 mg/day.
d) All of the above.
actually implemented by the prescriber or
Nonetheless, whilst the quantity of
interventions is important, quality is
even more so. Looking to the future, the
value of the service is likely to be closely
evaluated on behalf of the payee and
the onus is therefore on pharmacists
to ensure that the quality of clinical
interventions is high. Ensuring activity
addresses clinically significant issues
and is cost-effective for the payee is
essential if the service is to continue
being funded beyond the period
covered by the 5CPA. Figure 1 highlights
some examples of areas that may
deliver ‘added value’, which could be
Key learning points
• The new federally funded clinical
intervention service offers
pharmacists an opportunity to be
rewarded for demonstrating that
they are experts in medication
• The success of this service is likely
to be increased if interventions
are documented thoroughly,
delivered professionally, and provide
meaningful benefits to patients and
the health system.
prioritised when delivering the clinical
1. Peterson GM, Tenni PC, et al. Evaluation of clinical interventions
within community pharmacy (PROMISe II). Canberra:
Pharmacy Guild of Australia; 2007.
2. The Fifth Community Pharmacy Agreement (5CPA). Canberra:
Department of Health and Ageing/Pharmacy Guild of
3. 5CPA. Clinical Interventions Eligibility. At: www.5cpa.com.
4. 5CPA. Program Specific Guidelines Pharmacy Practice
Incentives (PPI). Canberra: Department of Health and Ageing/
Pharmacy Guild of Australia; 2012.
5. Standard and guidelines for pharmacists performing clinical
interventions. (Appendix 8). Canberra: Pharmaceutical Society
of Australia; 2011.
6. Peterson GM, Tenni PC, et al. Documenting clinical
interventions in community pharmacy (PROMISe III). Canberra:
Pharmacy Guild of Australia; 2011.
Links Archive Australian Pharmacist December 2012 February 2013 Navigation Previous Page Next Page